Bristol-Myers Squibb — Ethics Grade C

Bristol-Myers Squibb receives an overall ethics grade of C (51/100) on CancelCo's corporate accountability database. Sector: Pharmaceuticals. Market cap: Large Cap.

Category scores

• labor: 60
• privacy: 85
• consumer: 40
• environment: 65
• humanRights: 55

Documented incidents (3)

• Illegal Marketing Settlement (high, 2007) — Paid $515 million to settle allegations of illegal marketing of the antipsychotic drug Abilify and paying kickbacks to doctors to prescribe its drugs.
• Revlimid Monopoly Allegations (medium, 2021) — The company faced intense scrutiny from Congress over price hikes for the cancer drug Revlimid, which increased in price by over 20 times the rate of inflation.
• Hawaii Plavix Penalty (high, 2021) — A judge ordered the company and Sanofi to pay $834 million for failing to warn consumers in Hawaii that the blood thinner Plavix was ineffective for many people.

Documented good deeds

• Global Health Equity Initiative — Launched a $300 million commitment over five years to address health disparities and increase clinical trial diversity.

Ethical alternatives

• Gilead Sciences — Better performance in access to medicine indices in developing nations.